Molecular and functional analysis of complement factor I mutations in atypical haemolytic uraemic syndrome patients

2008 ◽  
Vol 45 (16) ◽  
pp. 4131
Author(s):  
Sara C. Nilsson ◽  
Leendert A. Trouw ◽  
Bruno O. Villoutreix ◽  
Veronique Fremeaux-Bacchi ◽  
Anna M. Blom
Immunobiology ◽  
2016 ◽  
Vol 221 (10) ◽  
pp. 1124-1130 ◽  
Author(s):  
Patrick J. Gleeson ◽  
Valerie Wilson ◽  
Thomas E. Cox ◽  
Seema D. Sharma ◽  
Kate Smith-Jackson ◽  
...  

2021 ◽  
Vol 14 (7) ◽  
pp. e244190
Author(s):  
Geminiganesan Sangeetha ◽  
Jaippreetha Jayaraj ◽  
Swathi Ganesan ◽  
Sreeapoorva Puttagunta

Complement-mediated kidney disease has been an evolving area in the field of nephrology. Atypical haemolytic uraemic syndrome (aHUS) is a rare thrombotic microangiopathy that affects multiple organs, particularly kidneys. The disease is characterised by a triad of haemolytic anaemia, thrombocytopenia and acute kidney injury (AKI). aHUS is most commonly caused by dysregulation of alternative complement pathway. In contrast to shiga toxin-associated haemolytic uraemic syndrome, diarrheal prodrome is usually absent in children with aHUS. We report a 2-year, 9-month-old boy who presented with acute dysentery and AKI. He had an unusual prolonged course of illness with hypocomplementaemia; hence, genetic testing was performed. He had a storming course in the hospital and succumbed to complications of the disease. Genetic study revealed digenic mutation in Complement Factor I and C3. Therefore, it is important to differentiate aHUS from other thrombotic microangiopathies to improve the outcome.


2007 ◽  
Vol 44 (16) ◽  
pp. 3920
Author(s):  
Sara C. Nilsson ◽  
Leendert A. Trouw ◽  
Nicolas Renault ◽  
Maria A. Miteva ◽  
Ferah Genel ◽  
...  

1986 ◽  
Vol 23 (6) ◽  
pp. 711-715 ◽  
Author(s):  
J. M. RASMUSSEN ◽  
B. TEISNER ◽  
I. BRANDSLUND ◽  
S.-E. SVEHAG

Gene Therapy ◽  
2021 ◽  
Author(s):  
Anna K. Dreismann ◽  
Michelle E. McClements ◽  
Alun R. Barnard ◽  
Elise Orhan ◽  
Jane P. Hughes ◽  
...  

AbstractDry age-related macular degeneration (AMD) is characterised by loss of central vision and currently has no approved medical treatment. Dysregulation of the complement system is thought to play an important role in disease pathology and supplementation of Complement Factor I (CFI), a key regulator of the complement system, has the potential to provide a treatment option for AMD. In this study, we demonstrate the generation of AAV constructs carrying the human CFI sequence and expression of CFI in cell lines and in the retina of C57BL/6 J mice. Four codon optimised constructs were compared to the most common human CFI sequence. All constructs expressed CFI protein; however, most codon optimised sequences resulted in significantly reduced CFI secretion compared to the non-optimised CFI sequence. In vivo expression analysis showed that CFI was predominantly expressed in the RPE and photoreceptors. Secreted protein in vitreous humour was demonstrated to be functionally active. The findings presented here have led to the formulation of an AAV-vectored gene therapy product currently being tested in a first-in-human clinical trial in subjects with geographic atrophy secondary to dry AMD (NCT03846193).


Sign in / Sign up

Export Citation Format

Share Document